912369-42-7 Usage
General Description
Methyl 3-(tert-butoxycarbonylamino)picolinate is a chemical compound with the formula C13H17NO5. It is an ester derivative of picolinic acid, containing a methyl group and a tert-butoxycarbonyl (Boc) protecting group attached to the nitrogen atom. Methyl 3-(tert-butoxycarbonylamino)picolinate has applications in the field of organic synthesis, particularly in the production of pharmaceuticals and agrochemicals. It is commonly used as a building block in the synthesis of complex organic molecules and drug intermediates. Methyl 3-(tert-butoxycarbonylamino)picolinate is also used in the study of chemical and biological processes, and its properties make it a valuable tool for researchers in various fields.
Check Digit Verification of cas no
The CAS Registry Mumber 912369-42-7 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 9,1,2,3,6 and 9 respectively; the second part has 2 digits, 4 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 912369-42:
(8*9)+(7*1)+(6*2)+(5*3)+(4*6)+(3*9)+(2*4)+(1*2)=167
167 % 10 = 7
So 912369-42-7 is a valid CAS Registry Number.
912369-42-7Relevant articles and documents
INHIBITORS OF BRUTON'S TYROSINE KINASE
-
Paragraph 00765, (2016/12/22)
Disclosed herein are reversible and irreversible inhibitors of Bruton's tyrosine kinase (Btk). Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are describeded, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.
SUBSTITUTED HETEROCYCLES AND THEIR USE AS CHK1, PDK1 AND PAK INHIBITORS
-
Page/Page column 129, (2008/06/13)
This invention relates to novel compounds of Formula (I) and to their pharmaceutical compositions and to their methods of use. These novel compounds possess CHK1 kinase inhibitory activity, PDK1 inhibitory activity and Pak kinase inhibitory activity and are accordingly useful in the treatment and/or prophylaxis of cancer.
